©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Genomic Cloning, Characterization, and Functional Analysis of the Major Surface Adhesin WI-1 on Blastomyces dermatitidis Yeasts (*)

(Received for publication, September 8, 1995)

Laura H. Hogan (§) Sam Josvai Bruce S. Klein (¶)

From the Departments of Pediatrics, Internal Medicine, and Medical Microbiology and Immunology and the Comprehensive Cancer Center, University of Wisconsin Medical School, University of Wisconsin Hospital and Clinics, Madison, Wisconsin 53792

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

WI-1 is a 120-kDa surface protein adhesin on Blastomyces dermatitidis yeasts that binds CD18 and CD14 receptors on human macrophages. We isolated and analyzed a clone of genomic WI-1 to characterize this key adherence mechanism of the yeast. The 9.3-kilobase insert contains an open reading frame of 3438 nucleotides and no introns. The amino acid sequence of native WI-1 matches the deduced sequence of genomic WI-1 at positions 757-769, 901-913, and 1119-1138, demonstrating the cloned gene is authentic WI-1. The complete coding sequence has 30 highly conserved repeats of 24 amino acids arrayed in tandem in two noncontiguous regions of the protein. The repeat sequence is homologous to the Yersiniae adhesin invasin, the C terminus displays an epidermal growth factor-like domain, and the N terminus has a short hydrophobic sequence that may be a membrane-spanning domain. The tandem repeats are predicted to be at the exposed surface of the protein, thereby explaining the adhesive properties of WI-1. The WI-1 promoter contains a CAAT box (nucleotide positions 2287-2290), TATA box(2380-2385), and CT motif(2399-2508). Transcription is initiated within the CT motif at nucleotide 2431. A 5.5-kilobase subclone containing the full coding sequence of WI-1 was expressed as a histidine-tagged fusion protein in Escherichia coli. Recombinant WI-1 has the expected molecular mass of 120 kDa, is strongly recognized in Western blots by rabbit anti-WI-1 antiserum, and binds human macrophage receptors in the same manner as native WI-1. This work clarifies a key adherence mechanism of B. dermatitidis and will permit further analysis of WI-1-mediated attachment to host cells, receptors, and extracellular matrix.


INTRODUCTION

Medically important fungi pose a serious health hazard, especially for the growing numbers of immunocompromised patients worldwide(1) . At the same time, there are few antifungal drugs, and little is known about pathogenic mechanisms that might serve as new drug or vaccine targets in the fungi. To establish themselves in a host, pathogens must be able to adhere to tissues. Characterization of adherence promoting molecules, or adhesins, has therefore yielded insights into a key mechanism of microbial invasion of the host. Several adhesins of the opportunistic fungus Candida albicans regulate attachment, invasion, and dissemination of the fungus and help explain the molecular pathogenesis of disseminated candidiasis(2, 3, 4) . However, adhesins of other medically important fungi have not been characterized.

Blastomyces dermatitidis is a dimorphic fungal pathogen that infects the host through inhalation of conidia(5) . Upon transformation into the pathogenic yeast phase, B. dermatitidis multiplies within the lung and disseminates via the blood stream and lymphatics to cause disease in the skin, bone, genitourinary tract, and brain(5, 6) . Inflammatory reactions occur at the initial site of infection and at these metastatic foci. Cellular immunity is the major protective response of the host in preventing progressive disease in blastomycosis (7, 8, 9, 10) . The interaction of B. dermatitidis yeasts with host macrophages is therefore a critical event in the pathological process.

WI-1 is a 120-kDa surface protein on B. dermatitidis yeasts (11) and the major target antigen of cellular (12) and humoral (13) immunity in infected humans. Analysis of a partial cDNA from cloned WI-1 showed 4.5 copies of a 25-amino acid repeat arrayed in tandem near the C terminus. The repeat sequence is similar to invasin, an adhesion-promoting protein on Yersiniae(14) . Binding studies demonstrated WI-1 is an adhesin, which mediates attachment of yeasts to macrophages; the 25-amino acid repeat interacts with both CR3 and CD14 receptors(15) . In view of the importance of adherence in understanding and intervening in the pathogenesis of invasive fungal diseases, and because of the key role of WI-1 in binding yeasts to host tissues, we sought to characterize WI-1 more carefully at the molecular level. We describe here the complete cloning of genomic WI-1 and express and functionally analyze the adhesive properties of mature recombinant WI-1. We show the striking finding that the full-length gene contains 30 copies of the invasin-like repeat within the coding sequence. This information sheds new light on a key adherence mechanism in this pathogenic fungus.


MATERIALS AND METHODS

Fungal Strains

American Type Culture Collection (ATCC) strains 26199 and 60636 were used for these studies (ATCC, Rockville, MD). These strains are virulent isolates that have been associated with human disease. Strain 26199 also is the parental isolate of a collection of genetically related strains of B. dermatitidis that differ in virulence in a murine model of blastomycosis(16) . Stock cultures of the strains were maintained in the yeast form on 7H10 agar enriched with oleic acid-albumin complex (Sigma) at 37 °C. Yeasts were grown in Erlenmeyer flasks containing brain heart infusion broth (Difco Laboratories, Detroit, MI) at 37 °C in a gyrator shaker at 120 rpm for 72 h. Cells were harvested by filtration through a sintered glass filter and washed with saline.

Extraction and Analysis of Genomic DNA

High molecular weight genomic DNA was extracted from spheroplasted yeast cells of ATCC strain 26199. Cells from a 50-ml culture were centrifuged for 5 min at 1000 times g, resuspended in 5 ml of 5 mM EDTA containing 10 ml of 2-mercaptoethanol, and incubated while rocking for 30 min at room temperature. The suspension was then centrifuged for 5 min at 1000 times g, and pelleted cells were suspended in 1.25 ml of a buffer containing 1 M sorbitol, 100 mM EDTA, 50 mM sodium citrate at pH 5.7, 2.5 mg/ml of lysing enzymes (Sigma), and 1% 2-mercaptoethanol. After incubation for 18 h at 37 °C, the treated cells were centrifuged for 6 min at 3000 rpm, washed three times with 1 M sorbitol, resuspended in 0.5 ml of Tris-EDTA containing 1% SDS, and heated for 20 min at 65 °C. After 0.1 ml of 5 M potassium acetate was added to the cell suspension, they were incubated on ice for an additional 30 min, centrifuged for 5 min at 12,000 rpm, and extracted twice with one volume of phenol-chloroform and once with chloroform alone. The genomic DNA was precipitated with ethanol, and resuspended in Tris-EDTA containing RNase A (20 mg/ml).

Genomic DNA was resolved over 1 h at 100 V on a 1% agarose gel and stained with ethidium bromide. For Southern analysis, genomic DNA digested with restriction enzyme was resolved overnight at 30 V on a 1% agarose gel, transferred to nitrocellulose, and probed using previously described methods(17) . A WI-1 cDNA designated p1.1 and described under ``Results'' was prepared as a purified NotI fragment and used as a probe. A 100-ng aliquot of the probe was radiolabeled with [alpha-P]dCTP to a specific activity of approximately 10^9 cpm/µg using random oligonucleotides as primers (Pharmacia Biotech Inc.). Washed Southern blots were used to expose Kodak XAR-5 film with intensifying screens at -80 °C.

Construction and Screening of B. dermatitidis Genomic Library

Genomic DNA cut with XbaI (Life Technologies Inc.) was ligated at a 1:1 molar ratio into 50 ng of an XbaI-cut, dephosphorylated phagemid vector, pBluescript II (SK) (Stratagene, La Jolla, CA), which contains transcriptional and translational start sequences from the lacZ gene. After ligation, the DNA was electroporated into competent Escherichia coli strain XL1-Blue (Stratagene), which was prepared as described(18) . Transformed E. coli were plated on LB agar containing 50 mg/ml ampicillin in 150-mm-diameter Petri plates (Falcon, Cockeysville, MD). After overnight growth at 30 °C, bacteria were replica-plated onto a fresh agar plate and onto a 150-mm nitrocellulose sheet (Schleicher & Schuell, Keene, NH).

The genomic library was screened for clones of WI-1 by colony hybridization (17) using the WI-1 cDNA p1.1 as a probe. Positive colonies were isolated from original replica plates, replated, and rescreened with the probe until they were purified.

WI-1 DNA and Protein Sequencing

Double-stranded, WI-1 genomic DNA was sequenced directly from minipreps of purified plasmid DNA (pBluescript plus insert) by the Sanger dideoxy chain termination method using a Sequenase 2.0 polymerase kit (U.S. Biochemical Corp.). To sequence WI-1 DNA in the region of the 25-amino acid repeats, deletion derivatives were made using the Erase-a-base kit (Promega, Madison, WI). Sequence primers homologous to the pSK vector polylinker were the T3 and SK primers (U.S. Biochemical Corp.). Sets of primers homologous to internal sequences in the DNA insert were purchased from Operon Technologies (Alameda, CA). Both nucleotide sequences and the derived amino acid sequences were used to search the GeneBank and EMBL data bases using programs supplied by the Genetics Computer Group(19) .

Protein sequencing was performed (Keck Facility, Yale University, New Haven, CT) on peptides of native WI-1 from ATCC strain 60636 (20) following treatment of WI-1 in situ in acrylamide gel slices with endoproteinase LysC and separation by narrow bore, reverse-phase high performance liquid chromatography (HPLC) (^1)using previously described techniques(21) . Peptides were selected for sequencing on Applied Biosystems instruments by screening HPLC fractions for purity using electrospray ionization mass spectrometric analysis.

Promoter Analysis

Sites of transcription initiation in the WI-1 promoter were determined by primer extension analysis. Three separate primers were utilized corresponding to positions 2513-2529 (5`-GAA TGG AGA GCT TTT CC-3`), 2519-2540 (5`-GAT TAG GGA ATG AAT GGA GAG C-3`), and 2711-2728 (5`-GGA AGT GCT CGC TAT ACT-3`) of the DNA sequence shown in Fig. 2. Primer extension probes were prepared by end labeling 10 pmol of DNA primer with [-P]ATP using T4 polynucleotide kinase (Pharmacia) in a total volume of 30 µl at 37 °C for 1 h. The kinase buffer consisted of 50 mM Tris-Cl, pH 7.6, 10 mM MgCl(2), 100 µM spermidine, 100 µM disodium EDTA, and 5 mM dithiothreitol. The reaction was terminated by heating at 65 °C for 10 min. Labeling efficiencies ranged from 2 to 5 times 10^5 cpm/ng. Labeled primers were purified over Sephadex G25 (Pharmacia) spin columns equilibrated with 10 mM Tris, pH 8.0, 1 mM EDTA. Two nanograms (1 times 10^6 cpm) of labeled oligonucleotide was coprecipitated with 5-20 µg of total RNA or 1-2 µg of poly(A) RNA as indicated. Extension reactions were performed essentially as described (22) except that annealing was done at 42 °C for 2 h. Reaction products were resolved on standard sequencing gels alongside sequencing reactions utilizing the same end-labeled primer.




Figure 2: Complete nucleotide and deduced amino acid sequence of genomic WI-1 in B. dermatitidis yeasts. The nucleotide sequence is numbered on the left. The start codon is underlined, the stop codon is designated by an asterisk, and the promoter elements are in boldface and underlined. The transcription initiation site at nucleotide 2431 is in uppercase. The deduced amino acid sequence is displayed below the nucleotide sequence and is numbered on the right. Deduced amino acids that correspond to those derived independently in peptide fragments of native WI-1 appear in boldface type; deduced residues that do not match the residues in the peptide are italicized. Nonmatching residues reflect variation between strains 26199 (genomic WI-1) and 60636 (peptide fragments); see Fig. 5, and (14) .




Figure 5: N-terminal amino acid sequence of internal peptide fragments of native WI-1 protein isolated from ATCC strain 60636. Underlined residues in italicized, boldface type are those that do not match the deduced sequence of genomic WI-1 from ATCC strain 26199 (see corresponding amino acid positions in the complete sequence of genomic WI-1 in Fig. 2). However, the peptide sequence shown matches identically the deduced amino acid sequence of a WI-1 cDNA cloned from ATCC strain 60636 (14) .



Subcloning, Expression, and Purification of Recombinant WI-1

The complete coding sequence of WI-1 was subcloned into the pQE 32 expression vector (Quiagen, Chatsworth, CA), which creates a fusion protein by placing 6 histidine residues at the N terminus of recombinant proteins and permits purification on a nickel affinity column(23) . Genomic WI-1 was digested using BspI (Life Technologies, Inc.), and the resulting 5.5-kb fragment was treated with Klenow fragment (Life Technologies, Inc.) to create blunts ends and then purified using Geneclean (Bio 101, La Jolla, CA) after separation in low melting point agarose. The purified 5.5-kb fragment was ligated in frame into the plasmid pQE 32 vector cut with BamHI and blunt-ended by Klenow treatment. Plasmid DNA was electroporated into competent E. coli strain XL1-Blue containing the repressor plasmid pRep4 (kanamycin^R), which tightly regulates the T7 promoter in pQE 32. Transformed E. coli was plated on LB agar containing 50 µg/ml ampicillin and 25 µg/ml kanamycin. Growing colonies were picked, and minipreps were prepared to characterize the plasmid DNA. In-frame WI-1 inserts were identified by restriction analysis of plasmid DNA and confirmed by sequence analysis.

For expression of recombinant WI-1, transformed E. coli was grown in LB media containing 100 µg/ml ampicillin and 25 µg/ml kanamycin in a gyrator shaker at 37 °C. When the density of the culture reached A at 0.6 (after about 6 h of growth), 5 mM isopropyl-1-thio-beta-D-galactopyranoside was added. Optimal production of the fusion protein was examined at 1-h intervals after induction. Bacteria were centrifuged at 5,000 times g for 15 min at 4 °C. A lysate was prepared by resuspending the pellet in 1 times gel-loading buffer (50 mM Tris, pH 6.8, 100 mM dithiothreitol, 2% SDS, 0.1% bromphenol blue, 10% glycerol) equivalent to 0.1 volume of the original culture. The lysate was heated to 100 °C for 3 min and centrifuged at 12,000 times g for 1 min at room temperature. Lysates were examined by SDS-polyacrylamide gel as described by Laemmli(24) . Gels were stained for protein with Coomassie Brilliant Blue.

Recombinant WI-1 containing 6 histidine residues at the N terminus was purified over Ni-NTA resin (23) according to the supplier's specifications. To assess antibody recognition of the fusion protein, Western blots of gels were performed as described(14) . Anti-WI-1 antisera used in these experiments were from immunized rabbits and blastomycosis patients in whom antibody responses to WI-1 had previously been demonstrated by radioimmunoassay(11) .

Functional Assays of WI-1-mediated Attachment to Human Macrophages

WI-1-mediated attachment to human monocyte-derived macrophages was quantified in vitro as described(15) . Briefly, polystyrene microspheres (1 micron diameter; Polysciences Inc., Warrington, PA) were coated with HPLC-purified native WI-1 or recombinant WI-1 using the method of Schlesinger and Horowitz(25) . Microspheres (2 times 10^8) were washed twice in 0.05 M carbonate-bicarbonate buffer, pH 9.6, and then were incubated in 1 ml of the same buffer containing 10 µg of native or recombinant WI-1 or human serum albumin (HSA) as a control for 24 h at 37 °C. The microspheres were centrifuged and then were incubated for 30 min at 37 °C in 1 ml of buffer containing 0.5% HSA to block any remaining protein binding sites. The microspheres were washed twice in carbonate-bicarbonate buffer containing 0.5% HSA and standardized to 2 times 10^7/ml in Dulbecco's phosphate-buffered saline containing 0.5% HSA and 5% glycerol. The amount of WI-1 bound to microspheres was quantified by immunofluorescent staining and flow cytometry as described (15) using WI-1-reactive monoclonal antibody AD3-BD6, which recognizes the 25-amino acid repeat(20) .

Human monocytes were purified from buffy coats by sequential centrifugation on Ficoll-hypaque and Percoll gradients and cultured in RPMI 1640 containing 12.5% human serum and 10 µg/ml gentamicin. Macrophages were harvested after 4-7 days, washed, and suspended to 0.5-1.0 times 10^6/ml in Hanks' balanced salt solution containing 20 mM HEPES, 0.25% bovine serum albumin, and 0.3 units/ml aprotinin. Five µl of macrophage suspension were added to each well of a Terasaki tissue culture plate, which had been previously coated with 1 mg/ml human serum albumin, and the cells were allowed to adhere for 1 h at 37 °C.

For binding assays, 5 µl (10^5) of WI-1- or HSA-coated microspheres were added to macrophage monolayers and incubated at 37 °C for 30 min. Unattached microspheres were removed by washing, and the monolayers then were fixed with 2% glutaraldehyde, 1% sucrose in 0.01 M phosphate buffer, pH 7.2. The attachment of microspheres to macrophages was quantified by counting the number of particles bound to 100 macrophages by phase-contrast microscopy on a Nikon diaphot-inverted microscope.

Peptide inhibition of the binding of microspheres was investigated by adding 5 µl of the inhibitor to the well just prior to the addition of the microspheres. The tandem repeat peptide inhibitor used in these experiments displays 4.5 copies of the repeat and was synthesized and purified in recombinant form as described previously(20) . For monoclonal antibody blocking of macrophage receptors, 5 µl of antibody (50 µg/ml) were added to each well, and the plates were incubated for 30 min at 4 °C before microspheres were added. Monoclonal antibodies (1B4, specific for the common beta-chain of CD18 receptors(26) ; 904, specific for the alpha-chain of CD11b/CD18(27) ; 3C10, specific for CD14(28) ; and 3G8, specific for the low affinity FcR of neutrophils, FcRIII, CD16(29) ) were generously provided by Dr. Simon Newman (University of Cincinnati College of Medicine, Cincinnati, OH).

The results of binding assays are presented as the percentage of binding, which is the percentage of macrophages binding one or more particles, and the attachment index, which is the total number of microspheres bound per 100 macrophages. All experimental points were performed in duplicate, and experiments were repeated with macrophages from three to five different donors.


RESULTS

Identity of cDNA Probes

In a previous report(14) , we described an incomplete, 1-kb WI-1 cDNA isolated from B. dermatitidis ATCC strain 60636. Subsequently, we screened additional cDNA libraries from ATCC strain 26199 to isolate the complete coding sequence for WI-1. cDNA synthesis reactions were primed with a mixture of oligo(dT) and a 30-base pair oligomer homologous to sequence at the 5` end of the available 1-kb cDNA. These efforts produced longer WI-1 cDNAs, although they were still incomplete at the 5` end. The work below was accomplished with the published 1-kb cDNA, designated BK1, and an additional larger WI-1 cDNA isolated from strain 26199, designated p1.1. (^2)cDNA p1.1, which overlaps with 477 nucleotides at the 5` end of cDNA BK1, extends further than BK1 toward the 5` end of WI-1 coding sequence. The overlap of these two cDNAs with respect to each other is shown in Fig. 1B. Sequence analysis of cDNA p1.1 (strain 26199) confirmed its identity as WI-1 but also demonstrated 13% sequence variation from cDNA BK1 (strain 60636) in the overlapping coding regions, indicating strain variation.^2 Because cDNA p1.1 contained WI-1 coding sequence missing from cDNA BK1, we used cDNA p1.1 to further analyze genomic WI-1 by Southern analysis. cDNA p1.1 was also used to screen a genomic library made from DNA of strain 26199 to eliminate problems associated with sequence variation.


Figure 1: Restriction analysis and mapping of genomic WI-1 in B. dermatitidis yeasts. Panel A displays a Southern analysis of genomic DNA from ATCC strain 26199 probed with WI-1 cDNA p1.1. Prior to analysis, DNA was digested with the restriction enzymes shown. Panel B displays a restriction map of the isolated, genomic WI-1 and respective size and orientation of WI-1 cDNAs p1.1 and BK1.



Restriction Analysis and Cloning of Genomic WI-1

We first used cDNA p1.1 as a probe in Southern analysis of 26199 genomic DNA to identify restriction fragments that might contain the complete WI-1 gene. cDNA p1.1 hybridized to a single 9.3-kb fragment of XbaI-cut genomic DNA. No smaller hybridizing fragments were observed, suggesting the gene might be intact on the 9.3-kb fragment. cDNA p1.1 also hybridized to a predicted 2.7-kb fragment of BglI-cut DNA (Fig. 1A).

Nearly 20,000 recombinants from an XbaI genomic DNA library of B. dermatitidis strain 26199 were screened by colony hybridization using p1.1 as the cDNA probe. Three independent clones were identified, and each contained the predicted 9.3-kb insert anticipated from the Southern analysis. Comparison of the three clones to WI-1 cDNAs p1.1 and BK1 by further restriction analysis and Southern hybridization confirmed the identity of the three clones as WI-1 genomic DNA.

One clone was studied more thoroughly to investigate whether the 9.3-kb genomic insert contained all of the WI-1 gene. A restriction map of the insert relative to the cDNAs is illustrated below (Fig. 1B). Overlapping WI-1 cDNAs (p1.1 and BK1) and vector sequence were used to probe Southerns of a BglI digest of the clone to define the orientation of the restriction fragments and the location of the WI-1 gene. We predicted that the 3.2-kb BglI fragment was most 5` and contained 2.8 kb of DNA extending beyond the 5` end of p1.1, sufficient to contain the remainder of the WI-1 gene.

Nucleotide and Deduced Amino Acid Sequence of Genomic WI-1

The complete nucleotide and deduced amino acid sequence of genomic WI-1 is shown in Fig. 2. Several features are noteworthy. The start codon is underlined at positions 2599-2601. The open reading frame is 3438 nucleotides, and the coding sequence contains no introns. Remarkably, there are a total of 30 highly conserved repeats of a 24-amino acid sequence that comprises much of the WI-1 protein, except at the N terminus and C terminus.

In a previous report(14) , we described a 25-amino acid repeat arrayed in tandem and present in 4.5 copies near the 5` end of the 1-kb WI-1 cDNA isolated from ATCC strain 60636. This repetitive sequence also was of interest for its homology over a stretch of 17 residues with the Yersiniae adhesin invasin. Recently, we demonstrated that the tandem repeat promotes WI-1-mediated attachment to macrophage CD18 and CD14 receptors(15) . The tandem repeat from genomic WI-1 of ATCC strain 26199 is 24 amino acids in contrast to the 25-amino acid repeat of the other strain. The sequence of the repeat of strain 26199 is HEKYDW(K/E/D/V)LW(N/D)KWCKD(F/P/S)YNC(D/E)WD(K/S)(F/S). Fig. 2, amino acids 407 to 430, illustrates an example of a copy of the repeat. Fig. 3A shows the alignment and homology of 17 residues of the WI-1 tandem repeat in these two fungal strains with invasin.


Figure 3: Homology of WI-1 with other sequences in the GenBank data base. Panel A shows sequence similarity between a 17-amino acid portion of the tandem repeat of WI-1 (total repeat is 24 amino acids in strain 26199 and 25 amino acids in strain 60636) and Yersiniae invasin. Vertical solid lines indicate identity between residues, vertical dashed lines indicate a conservative amino acid substitution. Panel B shows the similarity between a cysteine-rich sequence near the C terminus of WI-1 and the consensus sequence for epidermal growth factor-like domain(45) . Conserved cysteines are marked with asterisks.



The 30 repeats are clustered in two noncontiguous areas of the protein. In the first area, four repeats are arrayed in tandem near the N terminus, corresponding to amino acid positions 211-307. In the second area, 26 repeats are arrayed in tandem corresponding to amino acid positions 407-1031. The amino acid sequence flanking these two regions also displays repeat-like sequence, but with varying amounts of degeneracy. For example, the four highly conserved repeats near the N terminus are flanked on both the 5` side (amino acid positions 182-210) and the 3` side (positions 307-335) by an elongated repeat of 28 amino acids. Even longer, more degenerate repeat-like sequence (positions 144-182) or, in some instances, short 9- or 10-amino acid elements of the tandem repeat (positions 335-406) flank these two elongated repeats of 28 amino acids and also flank the 3` end of the 26 repeats arrayed in tandem.

We previously described sequence homology of a cysteine-rich, nonrepetitive sequence near the C terminus of WI-1 cDNA BK1 with epidermal growth factor (EGF)-like domains(14) . This sequence also is conserved in positions 1058-1093 of the deduced amino acid sequence of genomic WI-1 from ATCC strain 26199 ( Fig. 2and Fig. 3B).

The predicted molecular mass of the WI-1 protein coded by this nucleotide sequence is 146 kDa, which is in close agreement with the SDS-PAGE relative mobility of approximately 120 kDa for the native WI-1 protein. In addition, the deduced amino acid sequence indicates that the protein is rich in tryptophan (146 residues, 18.6 mol %), aspartic acid (161 residues, 12.7 mol %), lysine (126 residues, 11.0 mol %), tyrosine (95 residues, 10.6 mol %), and cysteine (90 residues, 6.4 mol %), as expected from previous published work on the amino acid composition of native WI-1(20) .

A Kyte-Doolittle (30) hydrophilicity plot of the deduced sequence suggests that the protein is predominantly hydrophilic, due mainly to the charge within the tandem repeat, but that the protein has a distinct hydrophobic sequence at the N terminus (spanning amino acids 1-22) indicative of a membrane-spanning domain (Fig. 4, upper panel). Analysis of the amino acid sequence adjacent to the amino-terminal hydrophobic domain failed to identify sequences of a signal peptide cleavage site(31) . Further analysis of the complete amino acid sequence using the Emini surface probability plot (32) indicates that the tandem repeats are predicted to be at the exposed surface of the WI-1 protein (Fig. 4, lower panel). This would explain their ability to mediate attachment of B. dermatitidis yeasts to human macrophage receptors.


Figure 4: Plots of hydrophilicity and surface probability for the deduced amino acid sequence of WI-1. DNAstar was used to access the hydrophilicity plot of Kyte-Doolittle (30) and the surface probability plot of Emini(32) .



Sequence of WI-1 Peptide Fragments

To verify that the cloned genomic gene is authentic WI-1, we obtained sequence from the WI-1 protein for comparison with the gene. Three internal peptide fragments of WI-1 from strain 60636 were sequenced (Fig. 5). The amino acid sequence from each peptide of native WI-1 matches closely the deduced sequence of genomic WI-1, corresponding to nucleotide positions 4866-4905, 5298-5337, and 5952-601 (Fig. 2). There are minor differences between the amino acid sequence of WI-1 peptides and the deduced sequence of genomic WI-1. However, the sequence of the peptides matches perfectly the published sequence of WI-1 cDNA BK1 (14) isolated from strain 60636, indicating that the observed differences may be due to variations in WI-1 sequence between strains 60636 and 26199.

Promoter Analysis to Identify Sites of Transcription Initiation

We inspected the nucleotide sequence upstream of the proposed translation initiation site for motifs characteristic of fungal promoters(33) . The elements we found are underlined in Fig. 2and include a CAAT box (nucleotide positions 2287-2290), a TATA box (positions 2380-2385), and a pyrimidine motif(2399-2508). These motifs are also correctly spaced both with respect to each other and to the initiating methionine(33) .

We performed primer extension analysis to determine where transcription of WI-1 mRNA initiates in this region. Using three separate primers, we mapped the initiating base to the C at position 2431 within the pyrimidine motif. A representative experiment is shown in Fig. 6. We consistently saw a doublet band at position 2431 and and 2432. The band at position 2432 most likely represents incomplete extension of the band at 2431 due to methylated nucleotides of the mRNA 5` cap(34) . In this experiment, we also saw a smaller band at position 2436. This band may represent incomplete extension or a second initiation site. The band was not always present using either this primer(2711-2728) or the other two primers.


Figure 6: Primer extension analysis of transcription initiation sites within genomic WI-1. The primer(2711-2728) was annealed to 20 µg of total RNA from strain ATCC 26199. The extended products representing initiation products are represented by arrows. Sequencing reactions using the same end-labeled primer are run alongside (in the order GATC). These results are representative of results observed when two other primers (positions 2513-2529 and 2519-2540) were also used to analyze transcription initiation sites within WI-1.



Direct evidence for promoter activity was accomplished in functional studies to be reported elsewhere. (^3)We confirmed that a 375-base pair piece of DNA spanning nucleotides 2223-2598 in the 5`-flanking region shown in Fig. 2has promoter activity. This sequence allowed expression of a hygromycin B resistance gene for transformation of B. dermatitidis yeasts.

Expression, Purification, and Immunological Analysis of Recombinant WI-1

To obtain large amounts of recombinant WI-1 to study its adhesive function in binding assays, we subcloned the WI-1 coding sequence in frame into the pQE 32 expression vector. Lysates of E. coli, transformed with the pQE vector containing a 5.5-kb WI-1 fragment and studied by SDS-PAGE, display a fusion protein of approximately 120 kDa by 4 h after induction with isopropyl-1-thio-beta-D-galactopyranoside (Fig. 7A). Recombinant WI-1 produced in E. coli migrates with an apparent molecular weight similar to that of native WI-1 on B. dermatitidis strain 26199. Purified, recombinant WI-1 is strongly recognized by rabbit anti-WI-1 antiserum in a Western blot (Fig. 7, B and C).


Figure 7: Expression and characterization of recombinant WI-1. Panel A shows a 7.5% SDS-PAGE gel of native WI-1 in crude, freeze-thaw extract of B. dermatitidis yeasts (ATCC strain 26199) in lane 1, compared with recombinant WI-1 in a crude lysate of E. coli in lane 2. A molecular size standard of 120 kDa is shown in the left margin. The gel is stained with Coomassie Blue. Panel B shows a 7.5% SDS-PAGE gel of native WI-1 in crude, freeze-thaw extract in lane 3, and purified, recombinant WI-1 following its purification in lane 4. The gel is stained with Coomassie Blue. Panel C shows a Western blot of native WI-1 in lane 5 and purified recombinant WI-1 in lane 6, which were probed with anti-WI-1 antiserum from an immunized rabbit.



Recombinant WI-1 Mediates Attachment to Human Macrophages

To study WI-1-mediated attachment to macrophages in vitro, we coated polystyrene microspheres with WI-1. Microspheres coated with native and recombinant WI-1 had large amounts of the protein on their surfaces when stained with a WI-1 reactive monoclonal antibody and studied by flow cytometry (Fig. 8). The isotype control antibody demonstrated that the detection of WI-1 on the microspheres was specific. In addition, no WI-1 was detected on the microspheres coated with HSA.


Figure 8: Flow cytometry analysis of WI-1 on B. dermatitidis yeasts and WI-1-coated microspheres. Binding of WI-1 specific monoclonal antibody AD3-BD6 was used to quantify the amount of bound native WI-1 (nWI-1) or recombinant WI-1 (rWI-1) adhered to latex microspheres. Staining of B. dermatitidis strain 26199 (positive control) and human serum albumin (HSA)-coated beads (negative control) with monoclonal AD3-BD6 is shown for comparison. Staining of yeasts and beads with the irrelevant IgG2a isotype control monoclonal Leu 5b also is shown. Results are representative of four separate preparations.



To investigate whether recombinant WI-1 retains the adhesive properties of the native protein, we tested binding of the protein-coated microspheres to human macrophages. Both native and recombinant WI-1-coated microspheres bound avidly to the macrophages, yielding percentages of binding between 73 ± 3% and 80 ± 4% and attachment indices between 597 ± 81 and 629 ± 76 (Table 1). In addition, a peptide displaying 4.5 copies of the tandem repeat effectively competed with native WI-1-coated microspheres for binding to the cells. The soluble peptide inhibited binding of these beads in a concentration-dependent manner, yielding a maximum of 81% inhibition at 1 mg/ml of peptide (Fig. 9A). In contrast, 1 mg/ml soluble human serum albumin as a control inhibitor had little effect on binding of the beads, yielding 5% inhibition.




Figure 9: Inhibition of the binding of WI-1-coated microspheres to human macrophages. Panel A shows binding of native WI-1-coated beads inhibited by the soluble ligand HSA, native WI-1, and a recombinant peptide with 4.5 copies of the tandem repeat. Macrophages adhered in the wells of a Terasaki culture dish were incubated with 5 µl of the various soluble ligands and 5 µl of native WI-1-coated beads for 60 min at 37 °C. Nonadherent beads were removed by washing, and the attachment index was quantified by phase-contrast microscopy. The data are the means ± S.E. from two experiments with different donors. Panel B shows inhibition of binding by monoclonal antibodies to CD18 and CD14. Macrophages were adhered in the wells of a Terasaki culture dish and incubated for 30 min at 4 °C with 5 µl of the various monoclonal antibodies at 50 µg/ml. Five microliters of native WI-1 (nWI-1)- or recombinant WI-1 (rWI-1)-coated beads was then added and incubated with macrophages for 30 min at 37 °C. Nonadherent beads were removed, and the attachment index was quantified as above. The data are the means ± S.E. from three experiments with different donors.



In a final set of experiments, we investigated whether recombinant WI-1-coated microspheres bound to macrophage CD18 and CD14 receptors as described previously for the native WI-1 adhesin(15) . Adherent macrophages were preincubated with monoclonal antibodies for 30 min at 4 °C and then were incubated with native and recombinant WI-1-coated microspheres for 30 min at 37 °C. Binding of both native and recombinant WI-1-coated microspheres to macrophages was markedly inhibited by monoclonal antibodies specific for the CD18 beta-chain, CD14, and the LPS binding site on CR3, but not by a monoclonal antibody specific for macrophage Fc receptors (Fig. 9B).


DISCUSSION

Despite the growing number of fungal infections in immunocompromised and normal hosts, little is known about the pathogenesis of fungal infections, especially adherence mechanisms. This is especially true for primary fungal pathogens, i.e. dimorphic fungi Histoplasma capsulatum, Coccidioides immitis, and B. dermatitidis, which are the most common. These pathogens can establish themselves and invade tissues of normal hosts and often cause large and widespread outbreaks of human infection, severe manifestations of disease, or both(35, 36, 37) . A better understanding of pathogenic mechanisms including adherence and adhesins in these fungi will ultimately improve treatment and control strategies. Adhesins could serve as vaccine candidates, similar to the situation in bacteria(38) .

We previously showed that the 120-kDa surface protein WI-1 on B. dermatitidis mediates attachment of the yeast to human macrophages (15) . In that study, WI-1-mediated binding to cells was governed, in part, by the 25-amino acid invasin-like, tandem repeat. Of interest is that the host's humoral immune response is directed against the tandem repeat. Anti-WI-1 antibodies in human serum(14) , and a panel of murine monoclonal antibodies (20) react almost exclusively with the repeat. Although cellular immunity is believed to play the key role in resistance to dimorphic fungi and other fungal pathogens, antibodies directed against the WI-1 tandem repeat may defend the host against B. dermatitidis; we speculate that interfering with attachment to host tissues may neutralize the pathogenicity of the fungus. Monoclonal antibodies directed against the capsular polysaccharide of Cryptococcus neoformans protect mice against experimental, cryptococcal infection(39) , and antibodies against a mannan adhesin of C. albicans protect mice against experimental, invasive candidiasis(40) . Thus, studies with B. dermatitidis, together with these on C. neoformans and C. albicans, suggest that immunity to surface components including adhesins may confer protection, and by inference, that adhesins of pathogenic fungi may be candidates for vaccine development.

In this study, we sought to clone the complete gene encoding WI-1 to characterize its binding domains at the molecular level and permit detailed analyses of WI-1-mediated adherence. Our efforts at cloning a full-length cDNA were unsuccessful but did yield a larger WI-1 cDNA that was useful for restriction analysis and screening of a genomic library to isolate full-length WI. In retrospect, a full-length cDNA was probably difficult to isolate because of the repetitive WI-1 sequence and inability to reverse transcribe it.

We isolated the full-length gene on a 9.3-kb fragment of XbaI-cut genomic DNA. Several lines of evidence indicate we have cloned WI-1 rather than some other WI-1-like gene sequence. First, positive clones were isolated by colony hybridization using a WI-cDNA probe, and the sequence of genomic WI-1 matches that of the probe. Second, rabbit anti-WI-1 antiserum reacts strongly with recombinant WI-1 expressed as a histidine-tagged fusion protein. Finally, and most importantly, amino acid sequence from three internal peptide fragments of native WI-1 match the sequence of the genomic gene, confirming its identity as WI-1.

Several features of the WI-1 coding and upstream sequence deserve comment. To our knowledge, WI-1 is the first adhesin cloned from a pathogenic fungus and one of the few genomic genes cloned from a pathogenic yeast. This offers insight into the structure and organization of the coding and upstream sequence of genomic genes in these eukaryotic pathogens. Small introns have frequently been observed in filamentous fungi and nonpathogenic yeasts(33) ; none were observed in the coding sequence of WI-1. However, common features in sequence flanking the start codon and characterizing promoter elements in nonpathogenic fungi were evident in the upstream sequence of WI-1.

In a study of 211 higher eukaryotic genes(41) , 205 had a purine three base pairs upstream from the ATG codon. In 79% of the instances, it was an A, and this is the case for WI-1. Elements of a fungal promoter include a CAAT box, TATA box, and a CT motif; all are present in the upstream sequence of WI-1. Moreover, the spatial relationships between these elements are preserved in WI-1. In many filamentous fungal genes, the transcription start site appears in or immediately downstream from a pyrimidine-rich sequence(33) . This has also been seen in yeasts, especially when genes are highly expressed or lack the usual TATA and CAAT motifs. An extreme example of a CT motif is the oliC gene of Aspergillus nidulans in which 96 bases of a 110-base pair stretch are pyrimidines(42) . In the 110-base pair stretch of the CT motif of WI-1, 84 bases are pyrimidines. Primer extension analysis demonstrates that transcription of WI-1 initiates at nucleotide position 2431, within the pyrimidine stretch.

The consensus sequence for the TATA box in fungi is TAT(A/T)A(A/T) (33) . TATAAA is most common and was observed in WI-1. The TATA box is usually found 20-40 base pairs upstream of the transcriptional start site, although it has been found as far away as -112 and -127 in Neurospora crassa (qa-IS gene) and A. nidulans (gdhA gene), respectively(33) . In WI-1, the TATA box is 52 base pairs upstream of the major transcription start site. In addition, the distance between the TATA box and CAAT box in WI-1 (90 base pairs) is similar to that in other fungal promoters.

In filamentous fungi, the CAAT box is usually found 60-120 base pairs upstream of the transcription start site, although longer distances have been found, including ones of -213 and -306 for two genes in A. nidulans(33) . In WI-1, the CAAT box is 145 base pairs upstream of the major transcription start site.

Perhaps the most intriguing and unanticipated observation here concerns the tandem repeat. We observed a total of 30 highly conserved copies of a 24-amino acid repeat arrayed in tandem and a small number of additional, degenerate repeats, which together comprised much of the WI-1 protein. Despite the repeat's slight variation in size and sequence between strains 60636 and 26199, both repeats show homology with sequence in Yersiniae invasin's adhesive domain, a 76-amino acid disulfide loop at the C terminus of the molecule(43) . Although invasin binds Yersiniae to mammalian cells through attachment to beta1 chain integrins such as the fibronectin receptor (44) , WI-1 binds B. dermatitidis to cells through attachment to beta2 chain integrins such as CD11/CD18 and to CD14(15) . The precise sequence(s) in the tandem repeat that bind these different receptors, the number of repeats needed for optimal binding, and the role of nonrepetitive sequence in promoting attachment are questions that need further study.

A nonrepetitive sequence at the C terminus of WI-1 is rich in cysteine and similar to the consensus sequence for EGF-like domains(45) . These domains have been described in molecules involved in cell-cell or cell-matrix interactions. Extracellular matrix components laminin and nidogen interact with one another and with cellular or microbial targets in part by EGF-like domains(46) . We speculate that the EGF-like domain of WI-1 contributes to adhesive functions of the molecule by interacting with extracellular matrix components. Deletion derivatives of the recombinant WI-1 will allow us to investigate whether and how the EGF-like domain binds B. dermatitidis to extracellular matrix components of the alveolar basement membrane and may help establish this pathogen in lung tissues of the host.


FOOTNOTES

*
This work was supported in part by National Institutes of Health Grants AI-31479 and AI-35681. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Recipient of National Institutes of Health National Research Service Award AI-08924.

Recipient of National Institutes of Health Research Career Development Award AI-01308. To whom correspondence should be addressed: University of Wisconsin Hospitals and Clinics, 600 Highland Ave., K4/434, Madison, WI 53792. Tel.: 608-263-9217; Fax: 608-263-0440.

(^1)
The abbreviations used are: HPLC, high performance liquid chromatography; kb, kilobase(s); HSA, human serum albumin; EGF, epidermal growth factor; PAGE, polyacrylamide gel electrophoresis.

(^2)
L. H. Hogan, S. Josvai, and B. S. Klein, unpublished data.

(^3)
L. H. Hogan and B. S. Klein, manuscript in preparation.


ACKNOWLEDGEMENTS

We thank Kathy Stone and Dr. Ken Williams (W. M. Keck Foundation Biotechnology Resource Laboratory, Yale University) for assistance in determining peptide sequences; Drs. Simon Newman and Sudha Chaturvedi for advice and assistance with binding experiments; the medical media staff at the William S. Middleton Memorial Veterans Hospital for photography and illustrations; and Dr. James Malter for comments on the manuscript.


REFERENCES

  1. Sternberg, S. (1994) Science 266, 1632-1634 [Medline]
  2. Calderone, R. A., and Braun, P. C. (1991) Microbiol. Rev. 55, 1-20
  3. Li, R. K., and Cutler, J. E. (1994) J. Biol. Chem. 268, 18293-18299 [Medline]
  4. Kanbe, T., Jutila, M. A., and Cutler, J. E. (1994) Infect. Immun. 60, 1972-1978 [Medline]
  5. Sarosi, G. A., and Davies, S. F. (1979) Am. Rev. Respir. Dis. 120, 911-938
  6. Bradsher, R. W. (1988) Inf. Dis. Clin. North. Amer. 2, 877
  7. Spencer, H. D., and Cozad, G. C. (1973) Infect. Immun. 7, 329-334 [Medline]
  8. Cozad, G. C., and Chang, C. T. (1980) Infect. Immun. 28, 398-403 [Medline]
  9. Longley, R. E., and Cozad, G. C. (1979) Infect. Immun. 26, 187-192 [Medline]
  10. Deepe, G. S., Jr., Taylor, C. L., and Bullock, W. E. (1985) Infect. Immun. 50, 183-189 [Medline]
  11. Klein, B. S., and Jones, J. M. (1990) J. Clin. Invest. 85, 152-161 [Medline]
  12. Klein, B. S., Sondel, P. M., and Jones, J. M. (1992) Infect. Immun. 60, 4291-4300 [Medline]
  13. Soufleris, A. J., Klein, B. S., Courtney, B. T., Proctor, M. E., and Jones, J. M. (1994) Rev. Infect. Dis. 19, 87-92
  14. Klein, B. S., Hogan, L. H., and Jones, J. M. (1993) J. Clin. Invest 92, 330-337 [Medline]
  15. Newman, S. L., Chaturvedi, S., and Klein, B. S. (1995) J. Immunol. 154, 753-761 [Medline]
  16. Brass, C., Volkmann C. M., Philpott, D. E., Klein, H. P., Halde, C., and Stevens, D. A. (1982) Sabouraudia 20, 145-158 [Medline]
  17. Maniatis, T., Fritsch, E. F., and Sambrook, J. (1989) Molecular Cloning: A Laboratory Manual , pp. 9.52-9.55, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  18. Dower, J. (1988) Mol. Biol. Rep. 6, 3-4
  19. Devereux, J., Haeberli, P., and Smithies, O. (1984) Nucleic Acids Res. 12, 387-395 [Medline]
  20. Klein, B. S., and Jones, J. M. (1994) Infect. Immun. 62, 3890-3900 [Medline]
  21. Stone, K. L., Elliot, J. I., Peterson, G., McMurray, W., and Williams, K. R. (1990) Methods Enzymol. 193, 389-412 [Medline]
  22. Nicolet, C., and Paulnock, D. (1994) J. Immunol. 152, 153-162 [Medline]
  23. Bush, G. L., Tassin, A., Friden, H., and Meyer, D. I. (1991) J. Biol. Chem. 266, 13811-13814 [Medline]
  24. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline]
  25. Schlesinger, L. S., and Horwitz, M. A. (1991) J. Exp. Med. 174, 1031-1038 [Medline]
  26. Wright, S. D., Rao, P. E., Van Voorhis, W. C., Craigmyle, L. S., Iida, K., Talle, M. A., Westberg, E. F., Goldstein, G., and Silverstein, S. C. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 5699 [Medline]
  27. Dana, N., Styrt, B., Griffin, J. D., Todd, R. F., III, Klempner, M. S., and Arnaout, M. A. (1986) J. Immunol. 137, 3259 [Medline]
  28. Van Voorhis, W. C., Steinman, R. M., Hair, L. S., Suban, J., Witmer, M. D., Koide, S., and Cohn, Z. A. (1983) J. Exp. Med. 158, 126 [Medline]
  29. Fleit, H. B., Wright, S. D., and Unkeless, J. C. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 3275 [Medline]
  30. Kyte, J., and Doolittle, R. F. (1982) J. Mol. Biol. 157, 105-132 [Medline]
  31. Von Heijne, G. (1983) Eur. J. Biochem. 133, 17-21 [Medline]
  32. Emini, E. A., Hughes, J. V., Perlow, D. S., and Boger, J. (1985) J. Virol. 55, 836-839 [Medline]
  33. Gurr, S. J., Unkles, S. E., and Kinghorn, J. R. (1987) in Gene Structure in Eukaryotic Microbes , Vol. 22, (Kinghorn, J. R., ed) pp. 93-139, IRL Press, Washington, D. C.
  34. Furuichi, Y., and Shatkin, A. J. (1989) Methods Enzymol. 180, 164-176 [Medline]
  35. Wheat, L. J., Slama, T. G., Eitzen, H. E., Kohler, R. B., French, M. L., and Biesecker, J. L. (1981) Ann. Intern. Med. 94, 331-337
  36. Pappagianis, D. (1988) in Current Topics in Medical Mycology , Vol. 2 (McGinnis, M. R., ed) pp. 199-238, Springer-Verlag, New York
  37. Beachey, E. H. (1981) J. Infect. Dis. 143, 325-345
  38. Klein, B. S., Vergeront, J. M., Weeks, R. J., Kumar, U. N., Mathai, G., Varkey, B., Kaufman, L., Bradsher, R. W., Stoebig, J. F., Davis J. P., and the Investigation Team (1986) N. Engl. J. Med. 314, 529-34
  39. Mukherjee, J., Scharff, M. D., and Casadevall, A. (1992) Infect. Immun. 60, 4534 [Medline]
  40. Cutler, J. (1994) in Seminar 10: How Fungal Cell Surfaces Contribute to Virulence , Annual Meeting of the American Society for Microbiology, Las Vegas, Nevada, 1994
  41. Kozak, M. (1984) Nucleic Acids Res. 12, 857-8872
  42. Ballance, D. J. (1986) Yeast 2, 229-236 [Medline]
  43. Leong, J. M., Morrissey, P. E., and Isberg, R. R. (1994) J. Biol. Chem. 268, 20524-20532 [Medline]
  44. Isberg, R. R., and Leong, J. M. (1990) Cell 60, 861-871 [Medline]
  45. Appella, E., Weber, I. T., and Blasi, F. (1988) FEBS Lett. 231, 1-4 [Medline]
  46. Martin, R., and Timpl, R. (1987) Annu. Rev. Cell Biol. 3, 57-86

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.